Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Subscribe To Our Newsletter & Stay Updated
